DOCSLIB.ORG

Lethal Mutagenesis of HIV with Mutagenic Nucleoside Analogs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lethal Mutagenesis of HIV with Mutagenic Nucleoside Analogs Proc. Natl. Acad. Sci. USA Vol. 96, pp. 1492–1497, February 1999 Genetics Lethal mutagenesis of HIV with mutagenic nucleoside analogs LAWRENCE A. LOEB*†,JOHN M. ESSIGMANN‡,FARHAD KAZAZI*§,JUE ZHANG*, KARL D. ROSE*¶, i AND JAMES I. MULLINS *Joseph Gottstein Memorial Cancer Research Laboratory, Department of Pathology, and iDepartment of Microbiology, University of Washington, Seattle, WA 98195; and ‡Department of Chemistry and Division of Toxicology, Massachusetts Institute of Technology, Cambridge, MA 02139 Communicated by Manfred Eigen, Max Planck Institute for Biophysical Chemistry, Go¨ttingen, Germany, December 14, 1998 (received for review November 1, 1998) ABSTRACT The human immunodeficiency virus (HIV) structure of the population. Within the quasispecies are drug- replicates its genome and mutates at exceptionally high rates. resistant viruses that are present early in infection before As a result, the virus is able to evade immunological and exposure to a drug, as well as mutant viruses that can easily chemical antiviral agents. We tested the hypothesis that a acquire additional mutations that render them drug resistant further increase in the mutation rate by promutagenic nucle- (10). oside analogs would abolish viral replication. We evaluated The exceptionally high rate of mutagenesis of RNA viruses deoxynucleoside analogs for lack of toxicity to human cells, (11, 12), coupled with the finding that most HIV virions in the incorporation by HIV reverse transcriptase, resistance to blood appear to be nonviable (13), suggest that the HIV repair when incorporated into the DNA strand of an genome is unable to tolerate many additional mutations RNAzDNA hybrid, and mispairing at high frequency. Among without a loss of viability. Thus, even a small increase in the candidates tested, 5-hydroxydeoxycytidine (5-OH-dC) ful- mutation rate might result in the virus population reaching an filled these criteria. In seven of nine experiments, the presence error threshold beyond which the population cannot be sus- of this analog resulted in the loss of viral replicative potential tained because of a loss of viral replication capacity and after 9–24 sequential passages of HIV in human CEM cells. infectivity. Here, we examined the capacity of mutagenic In contrast, loss of viral replication was not observed in 28 deoxynucleoside analogs to modify the fidelity of replication of control cultures passaged in the absence of the nucleoside HIV during sequential passages in culture and to induce lethal analog, nor with other analogs tested. Sequence analysis of a mutagenesis. portion of the HIV reverse transcriptase gene demonstrated a disproportionate increase in G 3 A substitutions, mutations MATERIALS AND METHODS predicted to result from misincorporation of 5-OH-dC into the cDNA during reverse transcription. Thus, ‘‘lethal mutagene- Serial Transfer Experiments. Stock preparations of HIV- 6 y sis’’ driven by the class of deoxynucleoside analogs repre- 1LAI containing approximately 10 infectious units ml were sented by 5-OH-dC could provide a new approach to treating titered by syncytium induction (14). HIV was added at a 3 HIV infections and, potentially, other viral infections. multiplicity of 0.01 to 1-ml aliquots of medium containing 2 105 CEM cells that were previously incubated for 1 hr with or without different deoxynucleoside analogs. After 4 hr at 37°C, Current therapies for the treatment of HIV infection include 1 the infected cells were washed twice with PBS (without Mg2 combinations of inhibitors of the viral reverse transcriptase 1 or Ca2 ) and resuspended in 1 ml of medium with or without (RT) and protease. Drugs that target the viral RT either are the analog in a 48-well plate. Half the volume of the medium nucleosides that terminate viral DNA synthesis, such as with fresh analog was replenished at 2 days. After 4–6 days, the zidovudine (ZDV), dideoxyinosine (ddI), and dideoxycytidine indicated amount of supernatant was transferred to fresh cells (ddC), or are nonnucleoside analogs that bind to a hydropho- that were preincubated with or without analog for 1 hr. This bic cavity adjacent to the polymerase active site, such as procedure was iterated for the indicated number of cycles; nevirapine (1). Unfortunately, the rapid evolution of HIV in aliquots of both cells and supernatants were frozen at each vivo results in the emergence of viruses resistant to each of passage. Virus production was monitored by measuring HIV these agents. Combination therapy involving RT and protease p24 core antigen in culture supernatants with the Abbott inhibitors has been very successful in reducing viral loads and, Antigen ELISA Kit. All experiments were carried out with a in principle, should reduce the outgrowth of resistant viruses. double-blind protocol. Even this approach, however, is limited by drug availability, Insertions of dNTPs by HIV RT. A59-32P-end-labeled patient compliance, and the likelihood that virus populations 15-mer DNA primer was hybridized to the 39 end of a 46-mer harbored by treated individuals will eventually develop drug DNA template containing either dG or dA at position 16 from resistance. its 39 end. The reaction mixture contained 25 mM TriszHCl The development of HIV resistance to host immunity or y (pH 8.0), 10 mM MgCl2,40mMKCl,2mMDTT,0.1mg ml chemotherapy results both from the high replication rate of the BSA, 50 nM template-primer, and the stated amount of either virus and from the infidelity of the HIV RT. HIV-1-infected dCTP or its 5-hydroxy analog 5-OH-dCTP. The concentration 10 individuals produce approximately 10 virions per day (2), and of HIV RT was adjusted such that the reaction was linear with the HIV RT produces one error per 2,000–5,000 nucleotides time and ,20% of the primer was extended. After incubation polymerized (3–7). As a result, HIV genomes within an at 37°C, the reactions were terminated by the addition of an infected individual do not exist as a homogeneous nucleotide sequence, but rather as a ‘‘quasispecies’’ (8, 9), an ensemble of Abbreviations: RT, reverse transcriptase; 5-OH-dCTP, 5-hy- related genomes in which selection operates at the level of the droxydeoxycytidine triphosphate; 5-OH-dC, 5-hydroxydeoxycytidine. †To whom reprint requests should be addressed at: University of The publication costs of this article were defrayed in part by page charge Washington, Department of Pathology, Box 357705, Seattle, WA 98195-7705. e-mail: [email protected]. payment. This article must therefore be hereby marked ‘‘advertisement’’ in §Present address: AMGEN, Inc., Thousand Oaks, CA 91320-1789. accordance with 18 U.S.C. §1734 solely to indicate this fact. ¶Present address: University of Maryland at Baltimore Dental School, PNAS is available online at www.pnas.org. Baltimore, MD 21201. 1492 Downloaded by guest on September 26, 2021 Genetics: Loeb et al. Proc. Natl. Acad. Sci. USA 96 (1999) 1493 equal volume of denaturing sample buffer. The samples were sisted of 30 cycles. A 1-ml aliquot of each reaction mixture was boiled and the 16-mer product was resolved from the 15-mer diluted into a second 50-ml PCR mixture containing inner substrate by electrophoresis through a 14% polyacrylamidey primers corresponding to nucleotides 2281–2318 and 2881– urea gel. The amount of product generated was quantitated by 2916 and amplified for an additional 20 cycles. The amplified PhosphorImager (Molecular Dynamics) analysis and the ki- DNA was ligated into the PCR II-TOPO TA cloning vector netic constants were calculated from Hanes–Woolf plots (15). (Invitrogen). The nucleotide sequence of the HIV inserts was Nucleoside Analogs. The nucleoside analogs initially tested determined by sequencing both strands, using forward and included the following compounds. 5-Hydroxydeoxycytidine reverse primers complementary to the adjacent M13 DNA. (5-OH-dC) is formed in DNA on exposure to reactive oxygen species (16). 5-OH-dCTP is incorporated into DNA by DNA polymerases and HIV RT (17, 18) and yields predominantly RESULTS z 3 z G C A T substitutions, although other mispairings have Lethal mutagenesis results from a progressive accumulation of been observed. When present in double-stranded DNA, 5-OH- mutations in the HIV genome because of the incorporation of dC is excised by Escherichia coli endonuclease III (Nth protein) mutagenic deoxynucleoside analogs during each round of viral or formamidopyrimidine-DNA glycosidase (19, 20) or by replication (Fig. 1). The analog is taken up by cells as a homologous enzymes in eukaryotic cells (21). In contrast, nucleoside and is phosphorylated by cellular kinases to the z when present in an RNA DNA hybrid, 5-OH-dC is resistant to corresponding deoxynucleoside triphosphate. The mutagenic 4 digestion (22). O -Methyl-dTTP is incorporated efficiently nucleoside triphosphate then can be incorporated during HIV into DNA by a number of DNA polymerases, including RTs RNA template-directed synthesis of the minus DNA strand. (23, 24). Incorporation into HIV cDNA followed by methyl- 3 We postulate that mutagenesis would occur more frequently in transferase-mediated DNA repair would yield G A substi- the HIV genome because of the incorporation of a mutagenic tutions (25). Even though there is evidence for repair of z 4 analog into an RNA DNA hybrid for the following reasons. O -methyl-dT by several pathways (26, 27), the rate of removal First, reverse transcription occurs in the cytoplasm, whereas from rat liver DNA (t of 20–60 hr) is very slow. O6- 1/2 repair of cellular DNA is a nuclear process. Second, DNA Methyl-dG is produced in DNA by alkylating agents and repair enzymes have evolved to utilize double-stranded DNA base-pairs with thymidine at high frequency (28–30), and the that is present in a B-type structure, whereas RNAzDNA triphosphate is incorporated into DNA by HIV RT as well as hybrids are in an A-type structure (38).
Load more

Recommended publications
  • Cdna Libraries and Expression Libraries
    Solutions for Practice Problems for Recombinant DNA, Session 4: cDNA Libraries and Expression Libraries Question 1 In a hypothetical scenario you wake up one morning to your roommate exclaiming about her sudden hair growth. She has been supplementing her diet with a strange new fungus purchased at the local farmer’s market. You take samples of the fungus to your lab and you find that this fungus does indeed make a protein (the harE protein) that stimulates hair growth. You construct a fungal genomic DNA library in E. Coli with the hope of cloning the harE gene. If you succeed you will be a billionaire! You obtain DNA from the fungus, digest it with a restriction enzyme, and clone it into a vector. a) What features must be present on your plasmid that will allow you to use this as a cloning vector to make fungal genomic DNA library. Your vector would certainly need to have a unique restriction enzyme site, a selectable marker such as the ampicillin resistance gene, and a bacterial origin of replication. Other features may be required depending upon how you plan to use this library. b) You clone your digested genomic DNA into this vector. The E. coli (bacteria) cells that you will transform to create your library will have what phenotype prior to transformation? Prior to transformation, the E. coli cells that you will transform will be sensitive to antibiotic. This allows you to select for cells that obtained a plasmid. c) How do you distinguish bacterial cells that carry a vector from those that do not? Cells that obtained a vector will have obtained the selectable marker (one example is the ampicillin resistance gene).
    [Show full text]
  • Gene Cloningcloningcloning
    GeneGeneGene CloningCloningCloning 20042004 SeungwookSeungwookKim Kim Chem.Chem. && Bio.Bio. Eng.Eng. Reference z T.A. Brown, Gene Cloning, Chapman and Hall z S.B. Primrose, Molecular Biotechnology, Blackwell 1 Why Gene Cloning is Important? z A century ago, Gregor Mendel : { Basic assumption (each heritable property of an organism) is controlled by a factor (gene). z In 1900, Mandel's law Æ the birth of genetics. z what these genes are and exactly how they work The Early Development of Genetics z In 1903, Sutton, W { Proposed that genes reside on chromosomes 2 z In 1910, Morgan, TH { Experimental backing on that --> development of the techniques for gene mapping (To establish the structure or structural details or location) { By 1922, a comprehensive analysis of the relative positions of over 2000 genes on the four chromosomes of the fruit fly. (Drosophilia melanogaster) z In 1944, Avery, MacLeod and McCarty z In 1952, Hershey and Chase { Experimental results were shown that DNA is the genetic material. { Conventional idea : genes were made of protein z In 1952-1966, Delbruck, Chargaff, Crick and Monod { The structure of DNA was elucidated. { The genetic code was cracked. { The process of transcription and translation were described. 3 The Advent of Gene Cloning z In the late 1960's ; The experimental techniques were not sophisticated. z In 1971 ~ 1973 ; A new experimental techniques were developed. { Recombinant DNA technology or Genetic engineering based on the process of gene cloning { This led to rapid and efficient DNA sequencing techniques that enabled the structures of individual genes to be determined. z In the 1990s ; started with massive genome sequencing projects including the human project.
    [Show full text]
  • 10. E. Coli Cloning Vector Pbr322
    10. E. coli cloning vector pBR322 Important questions based on it: A. (a) Name the organism in which the vector shown is inserted to get the copies of the desired gene. (b) Mention the area labelled in the vector responsible for controlling the copy number of the inserted gene. (c) Name and explain the role of a selectable marker in the vector shown. (AI 2010) B. (a) Identify the selectable markers in the diagram of E. coli vector shown below. (b) How is the coding sequence of -galactosidase considered a better marker than the ones identified by you in the diagram? Explain. (Delhi 2009) A. Explain the importance of (a) ori, (b) ampR and (c) rop in the E. coli vector shown below. (AI 2008) B. Draw pBR322 cloning vector. Label ‘ori’, ‘rop’ and any one antibiotic resistance site on it and state their functions. (AI 2015C) C. Draw a schematic diagram of the E. coli cloning vector pBR322 and mark the following in it: (a) ori (b) rop (c) ampicillin resistance gene (d) tetracycline resistance gene (e) restriction site BamHI (f) restriction site EcoR I (AI 2014C) D. Draw a schematic sketch of pBR322 plasmid and label the following in it: (a) Any two restriction sites. (b) Ori and rop genes. (c) An antibiotic resistant gene. (Delhi 2012) E. Identify A, B, C and D in the given diagram. (a) A-ori, B-ampR, C-tetR, D-HindIII (b) A-HindIII, B-tetR, C-ampR, D-ori (c) A-ampR, B-tetR, C-HindIII, D-ori (d) A-tetR, B-HindIII, C-ori, D-ampR (COMEDK) F.
    [Show full text]
  • Large-Insert BAC/YAC Libraries for Selective Re-Isolation of Genomic Regions by Homologous Recombination in Yeast
    doi:10.1006/geno.2001.6616, available online at http://www.idealibrary.com on IDEAL Article Large-Insert BAC/YAC Libraries for Selective Re-isolation of Genomic Regions by Homologous Recombination in Yeast Changjiang Zeng,1,5 Natalay Kouprina,2 Baoli Zhu,1,5 Al Cairo,1 Maarten Hoek,3 George Cross,3 Kazutoyo Osoegawa,1,5 Vladimir Larionov,2 and Pieter de Jong1,5,* 1Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA 2Laboratory of Biosystems and Cancer, National Cancer Institute, Bethesda, Maryland 20892, USA 3Laboratory of Molecular Parasitology, Rockefeller University, New York, New York 10021, USA 4Present address: Exelixis, South San Francisco, California 94080, USA 5Present address: Children’s Hospital Oakland, BACPAC Resources, 747-52nd Street, Oakland, California 94609, USA *To whom correspondence and reprint requests should be addressed. Fax: (510) 749-4266. E-mail: [email protected]. We constructed representative large-insert bacterial artificial chromosome (BAC) libraries of two human pathogens (Trypanosoma brucei and Giardia lamblia) using a new hybrid vector, pTARBAC1, containing a yeast artificial chromosome (YAC) cassette (a yeast selectable marker and a centromere). The cassette allows transferring of BACs into yeast for their fur- ther modification. Furthermore, the new hybrid vector provides the opportunity to re-isolate each DNA insert without construction of a new library of random clones. Digestion of a BAC DNA by an endonuclease that has no recognition site in the vector, but which deletes most of the internal insert sequence and leaves the unique flanking sequences, converts a BAC into a TAR vector, thus allowing direct gene isolation.
    [Show full text]
  • Molecular Cloning Plasmid-Based Cloning Vectors
    Page: 1 Molecular Cloning A glaring problem in most areas of biochemical research is obtaining sufficient amounts of the substance of interest. For example, a 10 L culture of E. coli grown to its maximum titer will only contain about 7 mg of DNA polymerase I, and many other proteins in much lesser amounts. Furthermore, only rarely can as much as half of any protein originally present in an organism be recovered in pure form. Eucaryotic proteins are even more difficult to obtain because tissue samples are usually only available in small quantities. With regards to the amount of DNA present, the 10 L E. coli culture would contain about 0.1mg of any 1000 bp length chromosomal DNA but its purification in the presence of the rest of the chromosomal DNA would be a very difficult task. These difficulties have been greatly reduced through the development of molecular cloning techniques. These methods, which are also referred to as genetic engineering and recombinant DNA technology, deserve much of the credit for the enormous progress in biochemistry and the dramatic rise of the biotechnology industry. The main idea of molecular cloning is to insert a DNA segment of interest into an autonomously replicating DNA molecule, a so-called cloning vector, so that the DNA segment is replicated with the vector. Cloning such a chimeric vector in a suitable host organism such as E. coli or yeast results in the production of large amounts of the inserted DNA segment. If a cloned gene is flanked by the properly positioned control sequences for RNA and protein synthesis, the host may also produce large quantities of the mRNA and protein specified by that gene.
    [Show full text]
  • High-Throughput Cloning and Characterization of Emerging Adenovirus Types 70, 73, 74, and 75
    International Journal of Molecular Sciences Article High-Throughput Cloning and Characterization of Emerging Adenovirus Types 70, 73, 74, and 75 Wenli Zhang 1, Kemal Mese 1, Sebastian Schellhorn 1 , Nora Bahlmann 1, Nicolas Mach 1, Oskar Bunz 1 , Akshay Dhingra 2, Elias Hage 2, Marie-Edith Lafon 3, Harald Wodrich 3 , Albert Heim 2 and Anja Ehrhardt 1,* 1 Virology and Microbiology, Center for Biomedical Education and Research (ZBAF), Department of Human Medicine, Faculty of Health, Witten/Herdecke University, 58453 Witten, Germany; [email protected] (W.Z.); [email protected] (K.M.); [email protected] (S.S.); [email protected] (N.B.); [email protected] (N.M.); [email protected] (O.B.) 2 Institut für Virologie, Adenovirus Konsiliarlabor, Medizinische Hochschule, 30625 Hannover, Germany; [email protected] (A.D.); [email protected] (E.H.); [email protected] (A.H.) 3 Microbiologie Fondamentale et Pathogénicité, Université de Bordeaux, 33076 Bordeaux, France; [email protected] (M.-E.L.); [email protected] (H.W.) * Correspondence: [email protected]; Tel.: +49-2302-926273 Received: 31 July 2020; Accepted: 31 August 2020; Published: 2 September 2020 Abstract: Recently an increasing number of new adenovirus types associated with type-dependent pathogenicity have been identified. However, identification of these clinical isolates represents the very first step to characterize novel pathogens. For deeper analyses, these adenoviruses need to be further characterized in basic virology experiments or they could be applied in translational research. To achieve this goal, it is essential to get genetic access and to enable genetic modification of these novel adenovirus genomes (deletion, insertion, and mutation).
    [Show full text]
  • Chapter 13 an Introduction to Cloning and Recombinant DNA Clones
    Chapter 13 An Introduction to Cloning and Recombinant DNA Clones • Genetically identical organisms or molecules derived from a common ancestor Cloning Plants from Single Cells Fig. 13.1 Cloning Animals • Animals were cloned more than 20 years ago • Two techniques – Embryo splitting – Nuclear transfer animalscience.ucdavis.edu library.thinkquest.org Embryo Splitting • Egg collected • Fertilized by in vitro fertilization (IVF) • Embryo is grown to 8–16 cells • Cells are separated • Separated cells grown into separate embryos • Embryos transplanted into surrogate mothers • May be used to clone any mammalian embryos, including humans Cloning by nuclear transfer www.biotechnologyonline.gov.au Cloning by nuclear transfer www.pnas.org Nuclear Transfer • First done in 1986 • More difficult • Nucleus is removed from an egg • Enucleated eggs are fused with other cells • Embryos are transplanted into a surrogate mother • In 1997, Dolly the sheep was the first mammalian clone from an adult donor cell Cloned animals Second addition Second chance Also cloned animals about to go extinct - gaur etc at Texas A&M Fig. 13.5 Cloning Mice by Injection of Nuclei from Adult Cells Problems - don’t live as long not carbon copies/identical develop diseases early very low success rate - 0.1 - 3% Dedifferentiation/reprogramming may not be complete or accurate Gene Cloning GOAL: To get enough copies of the gene to manipulate Gene Cloning vector Recombinant DNA Host Multiply Started with: few copies Ended with: Many copies. All identical to starting gene - CLONES Restriction enzymes Nobel Prize Werner Arber, Daniel Nathans and Hamilton O. Smith 1978 Restriction Enzymes Fig. 13.6 Inserting foreign DNA using restriction enzymes Ligase BamHI BamHI GGATCC GGATCC CCTAG G CCTAG G GATCC G G CCTAG Frequency of occurrence of restriction sites If DNA sequence has equal amounts of each base If bases are distributed randomly 6 base cutter (1/4)6 = 1 site in ~4000 bp 4 base cutter (1/4)4 = 1 site in 256 bp Common Restriction Enzymes Fig.
    [Show full text]
  • 3 Main Classification of Vectors (With Diagram)
    4/20/2020 3 Main Classification of Vectors (With Diagram) Privacy Policy | Join our Community :- Upload Now 3 Main Classification of Vectors (With Diagram) Article shared by : The classifications are: 1. On the Basis of Our Aim with Gene of Interest 2. On the Basis of Host Cell Used 3. On the Basis of Cellular Nature of Host Cell. Vector Classification # 1. On the Basis of Our Aim with Gene of Interest: The point is what we are targeting from our gene of interest — its multiple copies or its protein product. Depending on these criteria vec tors are of following two types: 1. Cloning Vectors: We use a cloning vec tor when our aim is to just obtain numer ous copies (clones) of our gene of interest (hence the name cloning vectors). These are mostly used in construction of gene libraries. A number of organisms can be used as sources for cloning vectors. Some are created synthetically, as in the case of yeast artificial chromosomes and bacte rial artificial chromosomes, while others are taken from bacteria and bacteriopha ges. In all cases, the vector needs to be genetically modified in order to accommo date the foreign DNA by creating an in sertion site where the new DNA will fit ted. Example: PUC cloning vectors, pBR322 cloning vectors, etc. 2. Expression Vectors or Expression construct: www.biotechnologynotes.com/recombinant-dna-technology/3-main-classification-of-vectors-with-diagram/395 1/64 4/20/2020 3 Main Classification of Vectors (With Diagram) We use an expression vector when our aim is to obtain the protein prod uct of our gene of interest.
    [Show full text]
  • Cloning Vector Puc119
    Cloning Vector pUC119 Product Information Sheet # V33402 SUMMARY shipped at RT; store at 4 °C For research use only Product pUC119 high copy phagemid vector for cloning and replication in E. coli and production of single-stranded DNA with helper phage M13KO7; suitable for “blue-white screening” technique. Description pUC119 is a high copy phagemid cloning vector for cloning and replication in E. coli and production of single-stranded DNA. It has been constructed by inserting the intergenic region (IG region) of the M13 phage DNA into the NdeI site of the pUC19 plasmid. This IG region contains the M13 origin of replication. Infection by the helper phage M13KO7 induces the production of single stranded pUC119 DNA, which is predominantly packaged into phage particles and then is released from bacterial cells. In addition, there is almost no contamination by the single stranded DNA of the helper phage. Using this system, single stranded DNA from large DNA fragments (up to 7 kb) can be stably obtained without deletion. pUC119 (as pUC19) bears the ampicillin resistance gene and the pMB1 origin of replication from pBR322. However, the pMB1 of pUC119 differs from the pBR322 origin by a single point mutation and the lack of the rop gene, leading to a high copy number. Additionally, pUC119 contains the lac operon of E. coli with CAP binding site, lac promoter (Plac), Lac repressor (LacR) binding site, and the 5’-terminal part of the lacZ gene encoding the N-terminal part of β-galactosidase (source – M13mp19 phage vector). This 5’-terminal part of the lacZ gene contains the multiple cloning site (MCS), and its expression is IPTG inducible.
    [Show full text]
  • AAV Helper-Free System
    AAV Helper-Free System Instruction Manual Catalog #240071 (AAV Helper-Free System) #240074 (pAAV-hrGFP Control Plasmid) #240075 (pAAV-IRES-hrGFP Vector) Revision C.0 For Research Use Only. Not for use in diagnostic procedures. 240071-12 LIMITED PRODUCT WARRANTY This warranty limits our liability to replacement of this product. No other warranties of any kind, express or implied, including without limitation, implied warranties of merchantability or fitness for a particular purpose, are provided by Agilent. Agilent shall have no liability for any direct, indirect, consequential, or incidental damages arising out of the use, the results of use, or the inability to use this product. ORDERING INFORMATION AND TECHNICAL SERVICES Email [email protected] World Wide Web www.genomics.agilent.com Telephone Location Telephone United States and Canada 800 227 9770 Austria 01 25125 6800 Benelux 02 404 92 22 Denmark 45 70 13 00 30 Finland 010 802 220 France 0810 446 446 Germany 0800 603 1000 Italy 800 012575 Netherlands 020 547 2600 Spain 901 11 68 90 Sweden 08 506 4 8960 Switzerland 0848 8035 60 UK/Ireland 0845 712 5292 All Other Countries Please visit www.agilent.com/genomics/contactus PREPROTOCOL SAFETY CONSIDERATIONS Note The safety guidelines presented in this manual are not intended to replace the BSL 2+ safety procedures already in place at your facility. The information set forth below is intended as an additional resource and to supplement existing protocols in your laboratory. Prior to use of the AAV Helper-Free System, we strongly recommend that the user become thoroughly familiar with the safety considerations concerning the production and handling of AAV and adenovirus.
    [Show full text]
  • Bacteriophage P1 Cloning System for the Isolation, Amplification, And
    Proc. Nati. Acad. Sci. USA Vol. 87, pp. 103-107, January 1990 Biochemistry Bacteriophage P1 cloning system for the isolation, amplification, and recovery of DNA fragments as large as 100 kilobase pairs (DNA packaging/pac cleavage/genome mapping/gene isolation) NAT STERNBERG E. 1. du Pont de Nemours & Co., Experimental Station, Central Research & Development Department, Wilmington, DE 19880-0328 Communicated by Sydney Brenner, September 18, 1989 (receivedfor review June 30, 1989) ABSTRACT The development of a bacteriophage P1 clon- clone large molecular weight DNAs, a bacteriophage P1 ing system capable of accepting DNA fragments as large as 100 cloning system has been developed and is described here. kilobase pairs (kbp) is described. The vectors used in this The P1 system permits the cloning, isolation, and recovery of system contain a P1 packaging site (pac) to package vector and DNA inserts as large as 100 kbp with an efficiency that is cloned DNA into phage particles, two P1 loxP recombination intermediate between that of cosmids and YACs. sites to cyclize the packaged DNA once it has been injected into a strain ofEscherichia coli containing the P1 Cre recombinase, a kan' gene to select bacterial clones containing the cyclized MATERIALS AND METHODS DNA, a P1 plasmid replicon to stably maintain that DNA in E. Phage and Bacterial Strains. Plcm-2 r-m- cl.100 am9.16 coli at one copy per cell chromosome, and a lac promoter- and Plcm-2 r-m- cl.100 am1O.1 are multiply mutated P1 regulated P1 lytic replicon to amplify the DNA before it is phage that were used here to prepare extracts for in vitro reisolated.
    [Show full text]
  • Introducing New DNA Into the Genome Requires Cloning the Donor
    Chapter 32: Genetic Engineering 32.2 Cloning Vectors Are Used to Amplify Donor DNA • Fragments of DNA are generated for cloning by cleavage with • Key Terms restriction enzymes. • • Cloning describes propagation of a DNA sequence by • A cloning vector is a plasmid or phage chromosome that is used incorporating it into a hybrid construct that can be replicated in to perpetuate a cloned DNA segment. a host cell. • Cloning vectors may be • A cloning vector is a plasmid or phage that is used to “carry” – bacterial plasmids, inserted foreign DNA for the purposes of producing more – phages, material or a protein product. – and cosmids (combo phage and plasmid), • Some cloning vectors have sequences allowing them to be propagated in more than one type of host cell. A donor DNA is generated Introducing new by cleavage by restriction DNA into the enzymes so that its ends genome requires can be joined to the ends cloning the donor of a cloning vector cleaved by the same restriction sequence, enzyme. delivery of the The hybrid molecule is then cloned DNA into the introduced into a bacterium cell, or yeast in which it can replicate to produce many more copies. and integration into the genome. 1 DNA can be released into target cells by methods that pass it across the membrane naturally, Each restriction enzyme cleaves a specific target such as a viral vector (in the same way as a viral infection) sequence or by encapsulating it in a (usually 4-6 bp long). liposome or sugar moieties The sites of cleavage on (which fuse with the membrane).
    [Show full text]